References
< Back

Characterize Cancer: Tissue Profiling¹

  • 741 genes for expanded genotyping

  • 47 promoter methylation genes

  • RNA-based fusion detection for a comprehensive view of common and rare fusions and splice isoforms

  • Pharmacogenomics to reduce risk of toxicity

Guardant Infinity is for research use only. Not for diagnostic purposes.

InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.

CHARACTERIZE CANCER

Profile tumors to detect current and emerging cancer biomarkers with our cutting-edge technology.

Characterize Cancer: Liquid Profiling¹

  • 750+ genes for expanded genotyping

  • Methylation-based tumor fraction to quantify disease burden

  • Pharmacogenomics to reduce risk of toxicity

Next >

Home‍ ‍Guardant Infinity™ for BioPharma‍ ‍Guardant360® CDx for BioPharma‍ ‍InfinityAI for BioPharma